Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market
The data the FDA has requested relates to specific individual performance characteristics of the assays on the microarray.
- The data the FDA has requested relates to specific individual performance characteristics of the assays on the microarray.
- As we always said, the commercialization of the initial SDS will only commence once the expanded Immunohematology microarray is available."
- Quotient disclaims any obligation to update these forward-looking statements because of new information, future events or circumstances or other factors.
- The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various jurisdictions.